Eligibility Screening For Non-Alcoholic Steatohepatitis (NASH): What to Expect
At Conquest Research, we are dedicated to aiding those who have Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) by providing access to clinical trials that may lead to viable treatments. To ensure the utmost safety of our participants, we require all potential candidates to undergo eligibility screening. Our screening process includes:
We require all of our clinical trial participants to join us for a meeting with our study’s medical personnel and affiliated staff. During this meeting, we assess your present health, the severity of your condition, and determine your medical eligibility for participation.
Before accepting any participants, we conduct a thorough evaluation of your eligibility to ensure that you meet all inclusion criteria. This ensures that we can provide top-notch care and support throughout the clinical trial.
As part of the initial evaluation process, we will assess your physical, mental, and emotional health. This will include filling out study questionnaires that will enable us to gain a deeper understanding of your suitability for the clinical trial.
All of these steps are vital measures that give our participants the best chance of success when participating in our Non-alcoholic Steatohepatitis (NASH) research.
Non-Alcoholic Steatohepatitis (NASH) is a severe type of Non-Alcoholic Fatty Liver Disease (NAFLD), characterized by an excessive accumulation of fat in the liver. This buildup can cause inflammation and damage to the liver cells, which can lead to scarring and cirrhosis. NASH is often referred to as a “silent disease” because it can develop without any noticeable symptoms. However, some people may experience fatigue, weakness, or abdominal pain. Risk factors for NASH and NAFLD include obesity, type 2 diabetes, high cholesterol, and high blood pressure. Treatment includes lifestyle changes around weight loss, exercise, and medication options to manage symptoms and prevent further liver damage.